Ivabradine and CV events in angina patients under review in Australia

23 June 2014

Australian pharma regulator the Therapeutic Goods Administration (TGA) is reviewing new information regarding ivabradine (Coralan), French independent drugmaker Servier’s cardiovascular drug approved in the European Union as Procoralan, identified in the preliminary results of a study into the medicine.

Ivabradine can be used to treat heart failure and stable angina. It is included on the Australian Pharmaceutical Benefits Scheme (authority required) for patients with chronic heart failure who meet the clinical criteria set out in the schedule.

The SIGNIFY study is evaluating the efficacy of ivabradine in patients who have a type of heart disease affecting the blood vessels that supply the heart, but no heart failure. The findings of this study are currently being evaluated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK